The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

被引：1
|
作者：
Statler, Abby [1 ]
Hobbs, Brian P. [2 ]
Radivoyevitch, Tomas [3 ]
Siebenaller, Caitlin [4 ]
Mukherjee, Sudipto [5 ]
Advani, Anjali S. [5 ]
Gerds, Aaron T. [5 ]
Nazha, Aziz [5 ]
Patel, Bhumika J. [5 ]
Carraway, Hetty E. [5 ]
Sekeres, Mikkael A. [5 ]
机构：
[1] Cleveland Clin, Canc Biostat, Shaker Hts, OH USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
[3] Quantitat Hlth Sci, Dept Quantitat Hlth Sci & Translat Hematol & Onco, Cleveland, OH USA
[4] Cleveland Clin Taussig Canc Inst, Leuekmia Program, Cleveland, OH USA
[5] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130319
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
16
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
    C Müller-Tidow
    P Tschanter
    C Röllig
    C Thiede
    A Koschmieder
    M Stelljes
    S Koschmieder
    M Dugas
    J Gerss
    T Butterfaß-Bahloul
    R Wagner
    M Eveslage
    U Thiem
    S W Krause
    U Kaiser
    V Kunzmann
    B Steffen
    R Noppeney
    W Herr
    C D Baldus
    N Schmitz
    K Götze
    A Reichle
    M Kaufmann
    A Neubauer
    K Schäfer-Eckart
    M Hänel
    R Peceny
    N Frickhofen
    M Kiehl
    A Giagounidis
    M Görner
    R Repp
    H Link
    A Kiani
    R Naumann
    T H Brümmendorf
    H Serve
    G Ehninger
    W E Berdel
    U Krug
    Leukemia, 2016, 30 : 555 - 561
  • [22] Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy
    Pleyer, Christopher
    Afzal, Amber
    Shomali, William
    Elson, Paul
    Jia Xuefei
    Bakdash, Suzanne
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    BLOOD, 2015, 126 (23)
  • [23] A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials
    Montalban-Bravo, Guillermo
    Huang, Xuelin
    Jabbour, Elias J.
    Borthakur, Gautam
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Cortes, Jorge E.
    Verstovsek, Srdan
    Kadia, Tapan M.
    Daver, Naval G.
    Wierda, William G.
    Alvarado, Yesid
    Konopleva, Marina
    Ravandi, Farhad
    Estrov, Zeev
    Jain, Nitin
    Alfonso, Ana
    Brandt, Pierola Mark
    Sneed, Troy
    Chen, Hsiang-Chun
    Yang, Hui
    Bueso-Ramos, Carlos E.
    Pierce, Sherry
    Estey, Elihu H.
    Bohannan, Zachary S.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
  • [24] Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia
    Devanlay, Camille
    Tavernier-Tardy, Emmanuelle
    Bourmaud, Aurelie
    Falk, Alexander Tuan
    Raberin, Helene
    Menguy, Sandrine
    Guyotat, Denis
    Magne, Nicolas
    Cornillon, Jerome
    BIOMEDICAL JOURNAL, 2015, 38 (03) : 235 - 243
  • [25] Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
    Versluis, Jurjen
    Flamand, Yael
    Haydu, Erika J.
    Vedula, Rahul S.
    Charles, Anne
    Copson, Kevin
    Wolach, Ofir
    Bendapudi, Pavan
    Belizaire, Roger
    Neuberg, Donna S.
    Luskin, Marlise R.
    Lindsley, R. Coleman
    BLOOD, 2020, 136
  • [26] The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
    Ball, Brian J.
    Hsu, Meier
    Devlin, Sean M.
    Arcila, Maria
    Roshal, Mikhail
    Zhang, Yanming
    Famulare, Chris A.
    Goldberg, Aaron D.
    Cai, Sheng F.
    Dunbar, Andrew
    Epstein-Peterson, Zachary
    Menghrajani, Kamal N.
    Glass, Jacob L.
    Taylor, Justin
    Viny, Aaron D.
    Giralt, Sergio S.
    Gyurkocza, Boglarka
    Shaffer, Brian C.
    Tamari, Roni
    Levine, Ross L.
    Tallman, Martin S.
    Stein, Eytan M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E171 - E175
  • [27] Impact of Red Blood Cell (RBC) Transfusion During Induction Chemotherapy in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML)
    Komrokji, Rami S.
    Khan, Awais M.
    Al Ali, Najla H.
    List, Alan F.
    Lancet, Jeffrey E.
    BLOOD, 2011, 118 (21) : 1537 - 1537
  • [28] AML -THERAPY: TIME FROM DIAGNOSIS TO INTENSIVE CHEMOTHERAPY INITIATION DOES NOT ADVERSELY IMPACT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Bertoli, Sarah
    ANNALS OF HEMATOLOGY, 2013, 92 : S3 - S3
  • [29] Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy
    Benton, Christopher B.
    Qiu, Peng
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pierce, Sherry A.
    Borthakur, Anisha
    Konopleva, Marina
    Cortes, Jorge E.
    Andreeff, Michael
    Quintas-Cardama, Alfonso
    BLOOD, 2012, 120 (21)
  • [30] Clinical predictors of resistant leukemia and induction deaths in patients on intensive induction chemotherapy for acute myeloid leukemia.
    Bishop, JF
    Matthews, JP
    Young, GAR
    Bradstock, K
    BLOOD, 1997, 90 (10) : 318 - 318
12345